Document:

<PAGE>   1

                                                                 EXHIBIT 10.3.52
                             PARTICIPATION AGREEMENT

         This Participation Agreement (the "Agreement") is made this 30th day of
November, 2000, by and between Neoprobe Corporation, a Delaware corporation
("Neoprobe") and Cira, LLC, a Delaware limited liability company ("Cira")
(collectively, the "Parties").

         WHEREAS, Neoprobe has exclusive rights to certain intellectual property
relating to the treatment of cancer using cellular therapy (hereinafter,
"Neoprobe's Intellectual Property").

         WHEREAS, Cira has exclusive rights to certain intellectual property
relating to the treatment of cancer using a novel cytokine factor (hereinafter,
"Cira's Intellectual Property").

         WHEREAS, the Parties desire to collaborate their intellectual property
to develop a cancer treatment regimen (the "Treatment Regimen") to license to a
third party.

         NOW, THEREFORE, in consideration of the mutual covenants exchanged
herein, the Parties agree as follows:

1.       DEVELOPMENT OF THE TREATMENT REGIMEN. Neoprobe grants to Cira a
         limited, nonexclusive license to use Neoprobe's Intellectual Property
         and technical information relating to the treatment of cancer using
         cellular therapy. Cira shall utilize Neoprobe's Intellectual Property
         and technical information in conjunction with Cira's Intellectual
         Property and technical information to develop the Treatment Regimen.
         Any new Intellectual Property developed by Cira in this effort will be
         jointly owned by Cira and Neoprobe, without obligation of accounting
         except as provided in Section 3 below. Upon development of the
         Treatment Regimen, the Parties shall endeavor to identify a third party
         to license the Treatment Regimen on mutually agreeable terms and
         conditions.

2.       EXPENSES. Neoprobe shall be responsible for the first $50,000.00 in
         direct costs (the "Initial Direct Costs") associated with the
         development of the Treatment Regimen. Cira shall submit invoices to
         Neoprobe, which state in reasonable detail the itemization of said
         Initial Direct Costs each calendar month and Neoprobe shall remit said
         amount, up to a total of $50,000.00 to Cira within thirty days of
         receipt of Cira's invoice. Except for the Initial Direct Costs, each
         party shall be responsible for all of its own costs and expenses
         incurred in connection with the development of the Treatment Regimen.

3.       REVENUE. In the event the Treatment Regimen is licensed to a third
         party, the Parties agree to allocate any and all revenue associated
         with the licensing of the Treatment Regimen in the following manner:

(a)      Development contract gross profit will be split equally between the
         parties.

(b)      Sales, licensing, and similar revenue, less direct costs associated
         therewith, will be split as follows:

         (I)    50:50 until this amount reaches $400,000;

         (ii)   thereafter, 80% to Neoprobe and 20% to Cira until Neoprobe
                receives one million nine hundred fifty thousand dollars
                ($1,950,000) in the aggregate from this amount; and
<PAGE>   2

Participation Agreement
Neoprobe and Cira
Page 2 of 5

         (iii)  50:50 between the parties thereafter.

4.       TERM OF AGREEMENT. In the event that on or before August 31, 2001, the
         parties enter into a joint development, strategic partnership, license
         or similar agreement with a third party relating to the Treatment
         Regimen, this Agreement shall continue in full force and effect until
         such time that such third party agreement expires. In the event the
         parties do not enter into such a third party agreement on or before
         August 31, 2001, this Agreement shall terminate on August 31, 20011
         unless the parties mutually agree otherwise in writing.

5.       INTELLECTUAL PROPERTY. The parties acknowledge that the Ohio State
         University Research Foundation ("OSURF") has granted each party their
         respective rights, pursuant to certain agreements and conditions, in
         the intellectual property, which the parties desire to contribute to
         the development of the Treatment Regimen. Each party represents and
         warrants to the other that its license of OSURF intellectual property
         is in full force and effect, and that this agreement does not violate
         the terms of such license. The parties each acknowledge that the
         Intellectual Property licensed hereby is subject to the rights of
         OSURF. The parties agree to maintain their respective agreements in
         good standing with OSURF and to notify the other party in the event of
         a termination or any material change in said agreements, which could
         adversely affect the marketability of the Treatment Regimen. In the
         event that a party's agreement(s) with OSURF is terminated, breached or
         otherwise adversely affected, and the breaching party fails to take
         action to correct such situation within thirty (30) days of notice from
         OSURF, the non-breaching party may institute action to correct the
         breach to the satisfaction of OSURF and shall be entitled to
         reimbursement from the breaching party for the cost of same.

6.       ADDITIONAL WORK BY CIRA. The parties acknowledge that in the event that
         they enter into an agreement with a third party to license or develop
         the Treatment Regimen, such third party is likely to require
         additional, specialized assistance ("Implementation Assistance") to
         commercialize the Treatment Regimen. Cira shall provide the
         Implementation Assistance by and through a separate agreement with the
         third party on such terms and conditions as Cira deems appropriate.
         Neoprobe shall not be entitled to any revenue from the Implementation
         Assistance provided by Cira, nor shall Neoprobe have any responsibility
         for expenses and costs associated with the provision of such
         Implementation Assistance.

7.       CONFIDENTIALITY AND USE. Cira acknowledges that the Intellectual
         Property and technical information of Neoprobe to be disclosed to it
         hereunder (collectively, "Confidential Information") is confidential
         and proprietary to Neoprobe. Unless expressly authorized in writing by
         Neoprobe, the Cira agrees to retain the Confidential Information in
         confidence and will not copy or disclose the Confidential Information
         to any third party or use the Confidential Information for any purpose
         other than as permitted by this Agreement. Cira agrees to protect the
         Confidential Information to the same extent and in the same manner that
         it would protect its own confidential information, but in no event will
         such efforts fall below a level of reasonable care, which shall include
         limiting disclosure to only those personnel who have a need to know for
         the purposes of developing the
<PAGE>   3

Participation Agreement
Neoprobe and Cira
Page 3 of 5

         Treatment Regimen. Cira will notify Neoprobe promptly upon discovery of
         the loss of any item containing Confidential Information and of any
         circumstances of which it has knowledge surrounding any unauthorized
         possession, use or knowledge of Confidential Information.

         Confidential Information may only be disclosed to Cira's employees and,
         even then, only to the extent that such employees have a specific need
         to know of the Confidential Information for the purpose of developing
         the Treatment Regimen. Before any of Cira's employees receives any part
         of the Confidential Information, such employee will be required to read
         this Agreement and to acknowledge and agree to abide by Cira's
         obligations under this Section 7.

8.       RELATIONSHIP OF THE PARTIES. Nothing in this Agreement is intended or
         shall be construed as forming a partnership, joint venture or
         employment relationship between Neoprobe and Cira.

9.       MATERIAL BREACH/RESOLUTION OF DISPUTES. Either party may terminate this
         Agreement upon a material breach of this Agreement by the other party,
         after providing the other party with thirty (30) days advance written
         notice of intent to terminate and setting forth the alleged breach, and
         failure of such other party to reasonably cure such breach or, in the
         event the nature of the breach is such that it cannot be corrected
         within thirty (30) days, to establish a corrective action plan
         reasonably acceptable to the other party within such time frame.

         The parties agree to initially attempt to resolve all disputes between
         them informally. In the event such resolution is not possible after
         thirty (30) days of informal efforts to resolve same, such disputes
         shall be submitted to an independent mediator, selected by mutual
         agreement of the parties within ten (10) days. In the event the parties
         cannot agree upon an independent mediator, or if such independent
         mediator is unsuccessful in resolving a dispute within thirty (30)
         days, the parties agree to submit to binding arbitration in accordance
         with the rules and procedures of the American Arbitration Association.

10.      NOTICES. Any notice required or permitted to be given hereunder to
         either party shall be deemed given if sent by hand delivery, registered
         or certified mail, return receipt requested, or by overnight mail
         delivery for which evidence of delivery is obtained by the sender, to
         such party at:

         If to Neoprobe:                         if to Cira:
         David C. Bupp, President                John L. Ridihalgh, President
         Neoprobe Corporation                    Cira, LLC
         425 Metro Place North                   2232 Summit Street
         Dublin, OH 43017-1367                   Columbus, OH 43201 t
         tel.: 793-7500                          tel.: 267-2472
         fax: 793-7522                           fax: 263-1060

11.      ASSIGNMENT. Neither this Agreement, nor any obligations required to be
         performed hereunder shall be assigned by either party without the prior
         express written consent of the other party. The provisions of, and
         obligations arising under, this Agreement shall extend to, be binding
         upon and inure to the benefit of the successors and assigns of each
         party hereto.
<PAGE>   4

Participation Agreement
Neoprobe and Cira
Page 4 of 5

12.      SEVERABILITY. If any part of this Agreement is deemed by a court of
         competent jurisdiction to be invalid, illegal, inoperative, or contrary
         to law or professional ethics, such part shall be reformed, if
         possible, to conform to law and ethics and the remaining parts of this
         Agreement shall be fully effective and operative to the extent
         reasonably possible. If any restriction contained in this Agreement is
         held by any court to be unenforceable or unreasonable, a lesser
         restriction shall be enforced in its place and the remaining
         restrictions shall be enforced independently of each other.

13.      ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
         between the parties hereto with respect to the Treatment Regimen. Oral
         statements or prior written materials not specifically incorporated in
         this Agreement shall not be of any force and effect. In entering into
         and executing this Agreement, the parties rely solely upon the
         representations and agreements contained in this Agreement and no
         others. No changes in or additions to this Agreement shall be
         recognized unless and until made in writing and signed by an authorized
         officer or agent of both parties

14.      GOVERNING LAW. This Agreement has been executed and delivered and shall
         be construed and enforced in accordance with the laws of the State of
         Ohio.

15.      WAIVER OF BREACH. No provision of this Agreement shall be deemed waived
         unless evidenced by a written document signed by an authorized officer
         or agent of the parties hereto. The waiver by either party of a breach
         or violation of any provision of this Agreement shall not operate as,
         or be construed to be, a waiver of any subsequent breach of the same or
         other provision of this Agreement.

16.      CONFIDENTIALITY OF TERMS. Neither party shall, without the prior
         written consent of the other party, disclose the terms of this
         Agreement or any part thereof to any third party, except as may be
         required by law or to the disclosing party's financial or legal
         advisors who are under a duty of confidentiality.

17.      SECTION HEADINGS. The section and other headings contained in this
         Agreement are for reference purposes only and shall not affect in any
         way the meaning or interpretation of this Agreement.

18.      EXECUTION. This Agreement and any amendments hereto may be executed in
         multiple counterpart originals. Each counterpart shall be deemed an
         original; but all counterparts together shall constitute one and the
         same instrument.

19.      ADDITIONAL ASSURANCE. The provisions of this Agreement are
         self-operative and do not require further agreement by the parties;
         provided, however, at the request of either party, the other party
         shall execute, except as otherwise provided in this Agreement, any
         additional instruments and take any additional acts as may be
         reasonably necessary to effectuate this Agreement.

21.      FORCE MAJEURE. Neither party hereto shall be liable nor deemed to be in
         default for any delay or failure in performance under this Agreement or
         other interruption of service or employment deemed resulting, directly
         or indirectly, from acts of God, civil or military authority, acts of
         public enemy, war, accidents, fires, explosions, earthquakes, floods,
         failure of transportation, strikes or other work
<PAGE>   5

Participation Agreement
Neoprobe and Cira
Page 5 of 5

         interruptions by either party's employees, or any similar or dissimilar
         cause beyond the reasonable control of either party hereto.

21.      AUTHORITY. Each signatory to this Agreement represents and warrants
         that he possesses all necessary capacity and authority to act for,
         sign, and bind the respective entity and employees thereof on whose
         behalf he is signing.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives as of the date first written
above.

NEOPROBE CORPORATION                     CIRA, LLC.

 /s/  David Bupp                         /s/  John L. Ridihalgh
--------------------------------         ---------------------------------------
By:  David C. Bupp, President            By:  John L. Ridihalgh, Managing Member

Date: November 30, 2000                  Date: 30 November 00
      ---------------------------        ---------------------------------------<PAGE>   1

                                                                    Exhibit 10.6
                                                                    ------------

                              EMPLOYMENT AGREEMENT
                              --------------------

         This AGREEMENT effective as of March 20, 2000, between ANTHONY & SYLVAN
POOLS CORPORATION (the "Company"), its successors and assigns, and William J.
Evanson (the "Employee").

         The Company agrees to employ the Employee as Executive Vice-President
and Chief Financial Officer of the Company, and the Employee agrees to serve the
Company as Executive Vice-President and Chief Financial Officer, all in
accordance with the terms and conditions set forth below.

1.       EMPLOYMENT

         (a) The Employee shall have such powers and duties as are customarily
performed by similar officers of companies of similar size as the Company or
such other titles, duties and powers as the board of directors shall reasonably
determine.

         (b) The term of this Agreement (the "Term") shall commence on the date
hereof and terminate on December 31, 2001. Unless, at least thirty days prior to
the end of the Term (whether the initial Term or as theretofore extended), the
Company shall have given written notice to the Employee of its intention not to
renew this Agreement, or the Employee shall have given written notice to the
Company of his unwillingness to renew this Agreement or the employment of the
Employee has otherwise been terminated during the Term, the Term shall
automatically be extended for an additional year.

2.       COMPENSATION

         The Employee will receive a base salary of $150,000.00 with annual
review for so long as this Agreement is continued, at which times increases will
be considered in good faith. In addition to the base salary, the Company shall
pay the Employee a bonus targeted at fifty percent (50%) of his base salary each
year ("Target Bonus"), and the Compensation Committee of the Company's Board of
Directors shall determine the appropriate target measures or goals in connection
with bonus compensation. Such bonus shall be determined and paid within thirty
(30) days after the Company's audited financial statements become available.

3.       INITIAL OPTIONS

         Pursuant to the terms of the Company's 1999 Long-Term Incentive Plan,
the Company will grant to the Employee options (the "Initial Options") to
purchase 25,000 shares of the Company's common stock (the "Shares") at the price
and subject to the terms and conditions set forth in a Non-Statutory Stock
Option Agreement (the form of which is attached hereto as Exhibit A) (the
"Option Agreement") to be entered into between the Company and the Employee.

4.       BENEFITS

         During the term of this Agreement, the Employee and his eligible
dependents shall be entitled to participate in and receive benefits under any
stock option or profit-sharing plan, health, disability, medical insurance or
other employee welfare or benefit plan or arrangement made generally available
by the Company during the term of this Agreement to its executives and key
management employees.

5.       CAR

         During the term of this Agreement, the Company shall provide the
Employee with an automobile allowance in the amount of $700 per month, subject
to periodic adjustment if appropriate.

6.       TRADE SECRETS: CONFIDENTIAL AND PROPRIETARY INFORMATION

         The Employee shall not at any time or in any manner, either directly or
indirectly, divulge, disclose or communicate to any person, firm, company,
corporation or business in any manner whatsoever any confidential information
relating to the business of the Company, including without limitation, the
Company's customer list, pricing policies, trade secrets, know-how, product
designs, strategic plans and similar types of information. The foregoing
restrictions shall not apply to the extent that such information (a) is
obtainable in the public domain, (b) becomes obtainable in the public domain,
except by reason of the breach by the Employee of the terms hereof, or (c) is

<PAGE>   2

required to be disclosed by rule of law or by order of a court or governmental
body or agency. This Section 6 shall remain in full force and effect for a
period of ten (10) years after expiration or termination of this Agreement for
any reason.

7.       COVENANT NOT TO COMPETE

         During the term of this Agreement and for a period of two (2) years
thereafter, the Employee will not, without the Company's prior written consent,
directly or indirectly engage in, make any investment in or have any interest in
any business in competition with the business of the Company; the Employee will
not advise, assist or render services either directly or indirectly to any
person, firm, company, corporation or business other than the Company with
reference to any business in competition with the business engaged in by the
Company during the Employee's employment by the Company; and the Employee will
not employ or offer employment to any employee or solicit, directly or
indirectly, any employee to leave the Company. Notwithstanding the foregoing,
the ownership of securities of any business competing with the Company, if such
securities are publicly traded on a national securities market and constitute
less than five percent (5%) of the outstanding stock thereof, shall not
constitute a violation of this provision. For purposes of this Section 7, a
business in competition with the Company shall mean any business engaged in the
manufacture, design, installation, processing, sale or distribution of products
that are the same as or similar to those of the Company at any time during the
term of this Agreement.

8.       TERMINATION OF CONTRACT

         It is agreed that subject to the provisions of Section 9 below, the
Company may terminate the employment of the Employee at any time with or without
cause by prior written notice to the Employee.

9.       SEVERANCE AND ENTITLEMENT

         In the event the Company decides to terminate the employment of the
Employee under the section entitled "TERMINATION OF CONTRACT" for any reason
and/or at any time, for reasons other than "Good Cause" (as hereinafter
defined), or determines not to renew this Agreement at the end of the Term
(whether the initial Term or as theretofore extended), the Employee will be
entitled to, in lieu of any and all other payments that may otherwise be due
under this Agreement, (i) a termination allowance in an amount equal to (a)
twelve months' salary at the then current rate of the Employee's pay and (b) the
annual Target Bonus to which the Employee would be entitled if his targeted
goals were attained for the fiscal year during which such termination occurs and
the Employee were employed during such entire year, multiplied by a fraction the
numerator of which is the number of days elapsed during the year through such
date of termination and the denominator of which is 365, and (ii) a continuation
of all medical and other employee benefits for the shorter of (a) twelve months
following the effective date of the termination and (b) the effective date of
coverage by similar plans of another employer. The termination allowance shall
be paid by the Company in twelve equal monthly installments beginning on the
first day of the first month following the effective date of termination;
provided, however, that the Employee continues to be in compliance with Sections
6 and 7 above. Any stock options vested and exercisable as of the date of such
termination may be exercised by the Employee for up to three (3) months after
the date that the Company delivers notice of such termination pursuant to the
terms of the Option Agreement. In the event the Company terminates this
Agreement for "Good Cause," which will be defined as the failure or refusal by
the Employee to perform his assigned duties, failure to adhere to Company policy
and/or the engaging by the Employee in misconduct injurious to the Company, the
Employee will not be entitled to receive any termination allowance, continuation
of benefits, or any other payments provided for in this Agreement, and any and
all unexercised stock options held by the Employee, both exercisable and
non-exercisable and unvested, shall be automatically forfeited and cancelled by
the Company pursuant to the terms of the Option Agreement.

10.      NOTICE OF TERMINATION

         Any intended termination of the employment of the Employee by the
Company or by the Employee shall be communicated by written notice of
termination ("Notice of Termination") to the other party hereto in accordance
with the section entitled "NOTICES" and shall state the grounds for termination.
Any purported termination of the Employee's employment which is not effected
pursuant to a Notice of Termination shall not be effective in discharging the
Employee.

11.      DEATH OR DISABILITY; RESIGNATION

         (a) Disability or Death. If the Employee is incapacitated for a period
of three (3) consecutive months so that he cannot perform his duties hereunder
on a full-time basis, then either the Company or the Employee may give written
notice to the other terminating the Employee's employment effective thirty (30)
days thereafter (the "Disability Termination Date"). The Company shall continue
to provide salary, medical coverage, disability and group life insurance to the
Employee for six (6) months after the earlier of the Disability Termination Date
or date of death. In the event of death or disability any stock options that are
not yet exercisable shall, pursuant to the terms of the Option Agreement, become
exercisable immediately. In the event of the Employee's death or disability, his
estate or the Employee may exercise any options held for up to one (1) year
after such date. Except as set forth herein, if the Employee

<PAGE>   3

dies prior to the termination of his employment or if notice of termination for
disability is given as provided above, the Company's obligations hereunder shall
terminate as of the earlier of the Employee's death or the Disability
Termination Date.

         (b) Resignation. If the Employee's employment is terminated by reason
of his voluntary resignation, all of the Company's obligations hereunder shall
terminate as of the termination date. All unexercised options, both vested and
unvested, shall be automatically forfeited and cancelled by the Company pursuant
to the terms of the Option Agreement.

12.      CHANGE IN CONTROL

         If there occurs a "change in control" (as hereinafter defined) of the
Company, any options granted to the Employee shall, pursuant to the terms of the
Option Agreement, become exercisable immediately by the Employee at any time.

         The term "change in control" means the first to occur of the following
events: (i) when any "person" as defined in Section 3(a)(9) of the Exchange Act
and as used in Sections 13(d) and 14(d) thereof, including a "group" as defined
in Section 13(d) of the Exchange Act, but excluding the Company and any employee
benefit plan sponsored or maintained by the Company (including any trustee of
such plan acting as trustee), directly or indirectly, becomes the "beneficial
owner" (as defined in Rule 13d-3 under the Exchange Act, as amended from time to
time), of securities of the Company representing more than fifty percent (50%)
of the combined voting power of the Company's then outstanding securities; or
(ii) the completion of a transaction requiring shareholder approval for the
acquisition of substantially all of the stock or assets of the Company by an
entity other than the Company or any merger of the Company into another company
and the Company is not the surviving company. Notwithstanding anything else in
this agreement, "Change in control" shall not include any change for reasons of
bankruptcy, insolvency or otherwise for the benefit of the Company's creditors.

13.      TAXES

         If all or any of the amounts payable to the Employee under this
Agreement (together with all other payments of cash or property, whether
pursuant to this Agreement or otherwise, including, without limitation, the
issuance of shares or options) constitutes "excess parachute payments" within
the meaning of Section 280G of the Code that are subject to the excise tax
imposed by Section 4999 of the Code (or any similar tax or assessment), the
amounts payable hereunder shall be increased to the extent necessary to place
the Employee in the same after-tax position as he would have been in had no such
tax assessment been imposed on any such payment paid or payable to the Employee
under this Agreement or any other payment that the Employee may receive in
connection therewith. The determination of the amount of any such tax or
assessment and the incremental payment required hereby in connection therewith
shall be made by the accounting firm employed by the Employee within thirty (30)
calendar days after such payment and said incremental payment shall be made
within five (5) calendar days after determination has been made. If, after the
date upon which the payment required by this Section 3(d) has been made, it is
determined (pursuant to final regulations or published rulings of the Internal
Revenue Service, final judgment of a court of competent jurisdiction, Internal
Revenue Service audit assessment, or otherwise) that the amount of excise or
other similar taxes or assessments payable by the Employee is greater than the
amount initially so determined, then the Company shall pay the Employee an
amount equal to the sum of: (i) such additional excise or other taxes, PLUS (ii)
any interest, fines and penalties resulting from such underpayment, PLUS (iii)
an amount necessary to reimburse the Employee for any income, excise or other
tax assessment payable by the Employee with respect to the amounts specified in
(i) and (ii) above, and the reimbursement provided by this clause (iii), in the
manner described above in this Section 3(c). Payment thereof shall be made
within five (5) calendar days after the date of such subsequent determination.
If, after the date upon which the payment required by this Section 3(c) has been
made to the Employee, it is determined that the Employee is entitled to receive
a refund of all or part of such payment, then the Employee shall pay to the
Company all amounts received by the Employee as a refund of any such overpayment
of excise or other taxes.

14.      AMENDMENT

         This Agreement may be amended at any time by a written agreement signed
by the Company and the Employee.

15.      WAIVERS

         The voluntary waiver by the Company or the Employee of any provision of
this Agreement or any breach thereof does not entail a waiver of any other
portion of this Agreement or this Agreement as a whole, or any subsequent breach
of the same provision, and does not affect the validity of this Agreement.

16.      GOVERNING LAW

         This Agreement, and all rights, duties and remedies hereunder shall be
governed by and construed and interpreted in accordance with the procedural and
substantive laws of the State of Ohio.

<PAGE>   4

17.      SEVERABILITY

         Should any portion of this Agreement be declared by a court of law
having competent jurisdiction over the persons and subject matter of this
Agreement to be invalid or unenforceable, the remainder of this Agreement shall
remain enforceable and in full effect. In the event that any provision of this
Agreement should be or becomes invalid for any reason, such provision shall
remain effective to the maximum extent permissible, and the parties shall
consult and agree on a legally acceptable modification giving effect to the
commercial objectives of the unenforceable or invalid provision, and every other
provision of this Agreement shall remain in full force and effect.

18.      SUCCESSORS

         This Agreement shall inure to the benefit of, and be enforceable by,
the parties' successors, representatives, executors, administrators or
assignees.

19.      NOTICES

         All notices or other communications hereunder shall be in writing and
shall be made by hand delivery, facsimile or registered or certified mail,
postage prepaid, return receipt requested, addressed as follows:

If to the Company, to:               Anthony & Sylvan Pools Corporation
                                     Mt. Vernon Square, Suite 300
                                     6690 Beta Drive
                                     Mayfield Village, OH 44143
                                     Attention: Chief Executive Officer

If to the Employee, to:              William J.  Evanson
                                     Anthony & Sylvan Pools Corporation
                                     Mt. Vernon Square, Suite 300
                                     6690 Beta Drive
                                     Mayfield Village, OH 44143

or at such other addresses as shall be furnished by the parties by like notice,
and such notice or communication shall be deemed to have been given or made as
of the date so delivered, if delivered personally; when receipt is acknowledged,
if sent by facsimile; and five calendar days after so mailed, if sent by
registered or certified mail.

         IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the date first above written.

                                     ANTHONY & SYLVAN POOLS CORPORATION

                                     By:
                                           ------------------------------
                                     Name: Stuart D. Neidus
                                     Its:  Chief Executive Officer

                                           -----------------------------
                                           William J. Evanson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]